March 31, 2023 09:00ET | Source FemPulse
SAN FRANCISCO, March 31, 2023 — FemPulse announced today the closing of its Series C financing. The company’s existing investors participated in the round, as well as two new large investors. The funding will support the company’s pivotal clinical trial and regulatory work in the United States, as well as the CE Marking commercial approval process for the EU.
“We are grateful to our broad investor base who have been supportive since our founding and continue providing such value-added to FemPulse. We are fortunate to have over a dozen investors with an MD or PhD who believe in our technology, as well as executives of medical technology and financial companies who can provide strategic support,” said Peter Fredericks, Chairman of FemPulse.
“This financing will allow us to bring my vision of a wireless female health platform, initially for the overactive bladder indication, through the clinical and regulatory stage in the US as well as to anticipated commercial clearance in Europe,” added Alexandra Haessler, MD, founder and
Chief Medical Officer.
About FemPulse Corporation
FemPulse Corporation is a bioelectronic medicine company developing a novel wearable bioelectronic platform for the personalized treatment of medical conditions in women. FemPulse’s vaginally-inserted, wearable neuromodulation device is intended to provide mild electrical nerve stimulation as a first-line alternative to pharmaceutical medications. The initial application is to treat the one in six women worldwide suffering from overactive bladder (OAB).
For more information, visit www.fempulse.com.
Investor Contact:
Peter Fredericks, Chairman
FemPulse Corporation
[email protected]
